Company intelligence / Profile preview

Neurescue

Ownership: Private
Development stage: Commercial

Overview

The NEURESCUE device provides rapid temporary aortic occlusion to increase blood flow to the heart and brain during cardiac arrest or severe bleeding. It can be deployed within one minute via femoral artery access. The company claims improved resuscitation rates and bridging to advanced treatments compared to standard CPR. Clinical data details are not publicly available but the product has received EU funding and regulatory support.

Therapeutic areas: CardiovascularHematology
Modalities: DeviceBalloon catheter
Industry: Therapeutic Medical Devices

Partnerships

European Union Horizon 2020 research program funding partner

Beyond the preview

Go deeper on Neurescue.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurescue.

Explore the full profile